Breaks Categories: News

WednesdayFeb 24, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as COVID-ID Labs, were ordered from XPhyto’s exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order consists of 9,600 individual tests; the tests are packaged in 200 kits of 48 tests each. The tests, which should arrive by mid-March 2021, will be used as samples for review and evaluation and will be primarily given to prospective distribution partners and licensees…

Continue Reading

WednesdayFeb 24, 2021 9:45 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Borkowski will remain as lead independent director of the board of directors. “Having served on AzurRx’s board since 2015, I am committed to ensuring a prosperous future for the company,” said Borkowski. “Under James’ leadership, AzurRx has strategically expanded…

Continue Reading

WednesdayFeb 24, 2021 9:32 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no more than 4,521,883 shares of common stock in the private placement. The common stock and associated warrants were issued for $1.95 each, with the warrants having an exercise price of $2 per share. The shares are exercisable immediately; however, they do have a five and…

Continue Reading

TuesdayFeb 23, 2021 10:12 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Present at Cowen 41st Annual Health Care Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics (“DTx”) market, today announced the company’s plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. According to the update, Dario's CEO, Erez Raphael and Rick Anderson, president and general manager for North America, are scheduled to present in a virtual setting at 11:00 a.m. ET on Monday, March 1, 2021. Interested parties can access the live and archived webcast via the company’s website. To view the full press release, visit https://ibn.fm/nac7n About DarioHealth Corp. DarioHealth is a leading, global digital-therapeutics…

Continue Reading

MondayFeb 22, 2021 10:46 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation…

Continue Reading

MondayFeb 22, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto's exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). It is anticipated that 3a will receive ISO 13485 medical device manufacturer approval by the end of February; European regulatory approval should be received by early March. The announcement noted that the market launch team consists of highly skilled clinical and pharmaceutical executives and service providers with the expertise and background to rapidly…

Continue Reading

FridayFeb 19, 2021 1:13 pm

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Publishes New Video for Plant-Based Investors

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) has released a new video that highlights the company’s value proposition for investors. The piece discusses PlantX's platform that serves as the digital face of the plant-based community, offering comprehensive capabilities that provide a robust and user-friendly ecommerce experience. The platform offers a wide variety of plant-based grocery items, from products to suit all pantry needs, as well as vitamins, cosmetics and even pet food. PlantX also offers meal delivery with options created by well-known plant-based chefs throughout the world, as well as weekly, easy-to-follow recipes. The one-stop experience includes Plant…

Continue Reading

FridayFeb 19, 2021 10:42 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants will be immediately exercisable at an exercise price of $5.00 per share and will expire five years…

Continue Reading

FridayFeb 19, 2021 10:03 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Slated to Host Investor Meetings at Global Healthcare Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced that CEO Erez Raphael will be participating in the upcoming SVB Leerink Global Healthcare Conference. The 10th annual SVB Leerink Healthcare Conference will be held Feb. 24–26, 2021. Raphael will participate in the  premiere event and is also scheduled to host investor meetings during the three-day virtual gathering. DarioHealth is recognized for providing one of the highest-rated diabetes and hypertension solutions available today with a team of experts that have impressive experience in the life sciences, behavioral science and software technology sectors. The company is covering new…

Continue Reading

ThursdayFeb 18, 2021 2:47 pm

BioMedNewsBreaks – Lincoln Health Network’s Upcoming Conference to Showcase Latest Innovations, Cover Every Facet of Clinical Doc Management

Lincoln Health Network, a renowned conference production company dedicated to shining a spotlight on the latest technologies and trends within the pharmaceutical, medical devices and biotech fields, today announced its plans to host the upcoming Clinical Document World conference. The event is set to take place in an entirely digital format on Feb. 24-26, 2021. The summit is designed to operate as a one-stop learning experience for life sciences professionals seeking to improve upon their clinical documentation process and will provide attendees with three days of sessions featuring faculty experienced in clinical documentation, trial master files, inspection readiness, risk management…

Continue Reading